Areas of Focus
- Pharmacology of Antitumor Drugs
Work Experience
- 2006-03~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher, Researcher
- 2001-09~2006-03 - National Cancer Institute, USA - Postdoctoral Fellow
- 1996-09~2001-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - PhD in Science
- 1992-09~1996-09 - East China Normal University - Bachelor of Science
Academic Background & Achievements
- 1996-09--2001-07 PhD in Science: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 1992-09--1996-09 Bachelor of Science: East China Normal University
Publications
- Discovery of Pyrido[2,3- d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment., Linghua Meng, 2024
- Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression., Linghua Meng, 2024
- Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K inhibitors., Linghua Meng, 2023
- Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation, Linghua Meng, 2023
- Targeting PI3K overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R, Linghua Meng, 2023
- Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy, Linghua Meng, 2022
- Repressing MYC by targeting BET synergizes with selective inhibition of PI3K against B cell lymphoma, Linghua Meng, 2022
- Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3K inhibitors in esophageal squamous cell carcinoma, Linghua Meng, 2022
- SAF-248, a novel PI3K delta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma, Linghua Meng, 2021
- Research progress in multi-targeted anti-tumor natural products, Linghua Meng, 2021
- PI3K inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism, Linghua Meng, 2021
- Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead., Linghua Meng, 2021
- Adaptive resistance to PI3K alpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells, Linghua Meng, 2021
- PI3K alpha inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma, Linghua Meng, 2021
- Corrigendum to 'Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer' Cancer Letter 342(2014) 159-166, Linghua Meng, 2020
- Progress in molecularly targeted anti-tumor drugs derived from natural products or their derivatives, Linghua Meng, 2020
- CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment, Linghua Meng, 2020
- Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo2,1-f1,2,4triazine derivatives, Linghua Meng, 2020
- Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors., Linghua Meng, 2020
- Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening, Linghua Meng, 2020
- Systematic combination screening reveals synergism between rapamycin and sutent against human lung cancer (vol 342, pg 159, 2014), Linghua Meng, 2020
- Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses Kras-mutated non-small cell lung cancer, Linghua Meng, 2020
- Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho -Naphthaquinone-Containing Natural Product, Linghua Meng, 2019
- Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3K alpha inhibition in breast cancer, Linghua Meng, 2019
- Design, synthesis, and biological evaluation of thieno3,2-dpyrimidine derivatives as potential simplified phosphatidylinositol 3-kinase alpha inhibitors, Linghua Meng, 2019
- Simultaneous inhibition of PI3K alpha and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
- Design, synthesis, and biological activity evaluation of (-)-6-O-desmethylantofine analogues as potent anti-cancer agents, Linghua Meng, 2019
- HRAS(G12s) mutant mediates resistance to a PI3K alpha inhibitor CYH33 in esophageal squamous cell carcinomas, Linghua Meng, 2019
- Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA(H1047R) accompanied with pro-tumorigenic secretome, Linghua Meng, 2019
- Simultaneous inhibition of PI3K and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
- PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment, Linghua Meng, 2019
- Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer, Linghua Meng, 2019
- Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K alpha-selective inhibitor CYH33 in breast cancer, Linghua Meng, 2018
- Discovery of clinical candidate methyl (5-(6-((4(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo2,1-f1,2,4triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) : A highly potent and selective PI3K alpha inhibitor for the treatment of advanced solid tumors, Linghua Meng, 2018
- Oncogene-induced senescence: a double edged sword in cancer, Linghua Meng, 2018
- The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8, Linghua Meng, 2018
- Oncogene-induced senescence: a double edged sword in cancer, Linghua Meng, 2018
- Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf V600E inhibitors, Linghua Meng, 2017
- Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K alpha-selective Inhibitors in Breast Cancer, Linghua Meng, 2017
- Discovery of a Novel Series of 7-AzaindoleScaffold Derivatives as PI3K Inhibitors with Potent Activity, Linghua Meng, 2017
- 6-OH-Phenanthroquinolizidine Alkaloid and Its Derivatives Exert Potent Anticancer Activity by Delaying S Phase Progression, Linghua Meng, 2017
- New Insights into PI3K Inhibitor Design using X-ray Structures of PI3K alpha Complexed with a Potent Lead Compound, Linghua Meng, 2017
- Targeting PI3K: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond, Linghua Meng, 2015
- Toward rapamycin analog (rapalog)-based precision cancer therapy, Linghua Meng, 2015
- PI3K isoform-selective inhibitors: next-generation targeted cancer therapies, Linghua Meng, 2015
- Identification of a Non-Gatekeeper Hotspot for Drug ResistantMutations in mTOR Kinase, Linghua Meng, 2015
- Design, synthesis and biological evaluation of acylhydrazone derivatives as PI3K inhibitors, Linghua Meng, 2015
- 新娃儿藤碱类似物抗肿瘤作用机制研究, Linghua Meng, 2015
- Toward rapamycin analog (rapalog)-based precision cancer therapy, Linghua Meng, 2015
- DW09849, a Selective Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Prevents PI3K Signaling and Preferentially Inhibits Proliferation of Cells Containing the Oncogenic Mutation p110 alpha (
Awards
- Pudong New Area 'Mingzhu Engineer' (2023): City-level, 2023
